Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis

(2015) Andreas Kronbichler et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms

(2013) D. Ricklin et al.   JOURNAL OF IMMUNOLOGY

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

(2013) H. Xiao et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis

(2012) Shen-Ju Gou et al.   KIDNEY INTERNATIONAL

Pathogenesis of Antineutrophil Cytoplasmic Autoantibody–Associated Small-Vessel Vasculitis

(2011) J. Charles Jennette et al.   Annual Review of Pathology-Mechanisms of Disease

Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

(2011) D J Dairaghi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inhibiting the C5–C5a receptor axis

(2011) Trent M. Woodruff et al.   MOLECULAR IMMUNOLOGY

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

(2010) M. J. Walters et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2

(2008) Hyun Lee et al.   IMMUNOLOGY AND CELL BIOLOGY

Identification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist

(2008) R. M. Brodbeck et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

C5a Receptor Mediates Neutrophil Activation and ANCA-Induced Glomerulonephritis

(2008) A. Schreiber et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The human complement fragment receptor, C5L2, is a recycling decoy receptor

(2008) Anne-Marie Scola et al.   MOLECULAR IMMUNOLOGY